IMJUDO combined with durvalumab improves overall survival in adults with unresectable hepatocellular carcinoma.

Clinical Efficacy of IMJUDO in Advanced Liver Cancer

The combination of IMJUDO and durvalumab has demonstrated a significant therapeutic benefit in the treatment of adult patients with unresectable hepatocellular carcinoma. In the HIMALAYA clinical trial, this regimen improved median overall survival compared to sorafenib, with a median OS of 16.4 months versus 13.8 months. The objective response rate was also higher, and the duration of response was prolonged. These results establish IMJUDO plus durvalumab as an effective first-line immunotherapy option for this patient population, offering a meaningful survival advantage.